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Abstract
During the last years the potential role of in vitro transcribed (IVT) mRNA as a vehicle to
deliver genetic information has come into focus. IVT mRNA could be used for anti-cancer
therapies, vaccination purposes, generation of pluripotent stem cells and also for genome
engineering or protein replacement. However, the administration of IVT mRNA into the tar-
get organ is still challenging. The lung with its large surface area is not only of interest for
delivery of genetic information for treatment of e.g. for cystic fibrosis or alpha-1-antitrypsin
deficiency, but also for vaccination purposes. Administration of IVT mRNA to the lung can
be performed by direct intratracheal instillation or by aerosol inhalation/nebulisation. The lat-
ter approach shows a non-invasive tool, although it is not known, if IVT mRNA is resistant
during the process of nebulisation. Therefore, we investigated the transfection efficiency of
non-nebulised and nebulised IVT mRNA polyplexes and lipoplexes in human bronchial epi-
thelial cells (16HBE). A slight reduction in transfection efficiency was observed for lipo-
plexes (Lipofectamine 2000) in the nebulised part compared to the non-nebulised which
can be overcome by increasing the amount of Lipofectamine. However, Lipofectamine was
more than three times more efficient in transfecting 16HBE than DMRIE and linear PEI per-
formed almost 10 times better than its branched derivative. By contrast, the nebulisation
process did not affect the cationic polymer complexes. Furthermore, aerosolisation of IVT
mRNA complexes did neither affect the protein duration nor the toxicity of the cationic com-
plexes. Taken together, these data show that aerosolisation of cationic IVT mRNA com-
plexes constitute a potentially powerful means to transfect cells in the lung with the purpose
of protein replacement for genetic diseases such as cystic fibrosis or alpha-1-antitrypsin
deficiency or for infectious disease vaccines, while bringing along the advantages of IVT
mRNA as compared to pDNA as transfection agent.
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Introduction
The lung with its large surface area is an attractive target organ for the delivery of drugs as it
can be approached topical via the airways without bringing along the drawbacks typical for
administration via the blood stream. Moreover, it also allows higher drug concentrations to
be deposited intrapulmonary at the site of action. In this context, nucleic acid delivery to this
organ presents a promising therapeutic approach to substitute mutated genes causing such
diseases as cystic fibrosis or alpha-1-antitrypsin deficiency [1–3]. Administration of gene vec-
tors to the lung can be performed by direct intratracheal instillation or by aerosol inhalation/
nebulisation. The latter approach signifies a non-invasive and painless method of pulmonary
administration. The stability and functionality of plasmid DNA (pDNA) complexes after
nebulisation have been demonstrated in various earlier studies [1–6]. It has been shown that
pDNA resistance against shear forces depends on the strand length, its conformation (circu-
lar versus linear) as well as on the nebulisation time [6]. Complexing pDNA with cationic
carriers such as polyethylenimine (PEI) resulted in an increased resistance to shear-induced
degradation [7–9] and enhanced gene expression in vivo [10]. Similarly, stabilization of
pDNA with a lipid-peptide formulation improved its biological functionality following nebu-
lization [11]. All studies published up to now employed pDNA and none investigated the
potential of in vitro transcribed (IVT) messenger RNA (mRNA) delivery to the lung via
aerosolisation.
When compared to the delivery of pDNA, employment of IVT mRNA may bring along
several advantages. Firstly, IVT mRNA does not need to reach the nucleus to be functional,
secondly, unlike pDNA, IVT mRNA does not integrate into the genome and therefore there
seems to be no risk of insertional mutagenesis [12, 13]. In addition, production of IVT mRNA
might be less expensive compared to pDNA. Those aspects are obviously very important in
the context of future clinical applications. There are a few major problems though, which
should be tackled before considering IVT mRNA as a therapeutic molecule. Since ribonucle-
ases (RNases) are resilient and ubiquitously present enzymes, IVT mRNA to be delivered
should be well protected against their activity. This problem could be solved by employing cat-
ionic carriers, which are known to protect pDNA against degradation by DNases [12].
Another potential drawback regarding IVT mRNA is the transient character of its translation
into proteins due to its limited longevity. Expression times range from hours to several days.
Stability and intracellular half-life of exogenously delivered IVT mRNA can be improved by
addition of a series of adenine nucleotides to its 3’ end (a so-called polyA tail) [12, 14, 15],
incorporation of a suitable cap analogue [14, 15], and employment of modified nucleotides for
its synthesis [14, 16–20].
In this context, IVT mRNA delivery to the lung could be a promising strategy for protein
substitution and vaccination strategies against infectious diseases. Application of IVT mRNA
by aerosolisation would be a highly acceptable and tolerable route of administration for the
patient. Therefore, in this study we evaluated the resistance of IVT mRNA-cationic carrier
complexes against the nebulisation process. To analyse stability of IVT mRNA lipoplexes Lipo-
fectamine 2000 and DMRIE C has been chosen due to the fact that both liposomes are well
characterized and have shown favourable results in the context of IVT mRNA mediated trans-
fection. To assess stability of IVT mRNA polyplexes polyethylenimine has been selected due to
the fact that PEI had been shown to have increased resistance to shear-induced degradation in
earlier studies when using pDNA. To that end transfection efficiencies of nebulised mRNA
complexes were analysed. The future goal of the study is the development and characterization
of an aerosol delivery platform for IVT mRNA to the lungs, to be applied for vaccination pur-
poses, treatment of genetic diseases and other pathological lung conditions.
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Materials and Methods
Cell culture conditions
The human bronchial epithelial cell lines 16HBE (generously provided by Dieter C.
Gruenert, University of California at San Francisco, CA, USA) were cultured either in
Eagle’s Minimal Essential Medium (16HBE; GE Healthcare, Munich, Germany) supplemented
with 10% heat-inactivated fetal bovine serum (FBS) and 100 U/ml penicillin and 100 μg/ml
streptomycin (all from GE Healthcare, Munich, Germany) at 37°C in a humidified atmosphere
(95% air, 5% CO2).
IVT mRNA transfection complexed to cationic lipids
Cells were seeded at a density of 3 x 104 (16HBE) in 96-well plates one day before transfection
to reach 80–90% confluence. Stabilized, non-immunogenic mRNA encoding Metridia lucifer-
ase (MetLuc SNIM RNA; generously provided by ethris GmbH, Martinsried, Germany) or
enhanced green fluorescent protein (EGFP SNIM RNA) was complexed with Lipofectamine
2000 (Invitrogen, Germany) or DMRIE C (Invitrogen, Germany) at different charge ratios (N/
P ratios). DMRIE C is a 1:1 (M/M) liposome formulation of the cationic lipid DMRIE
(1,2-dimyristyloxy-propyl-3-dimethyl-hydroxy ethyl ammonium bromide) and cholesterol.
100 ng of mRNA were added per well. The complexes were prepared in OptiMem (Invitrogen,
Germany) and incubated with cells in this medium or sodium chloride (0.9%) for 2h. Subse-
quently, the lipoplexes were removed and culture medium containing supplements was added.
Transfection efficiency was determined at indicated time points.
IVT mRNA transfection complexed with cationic polymers
Cells were seeded at a density of 3 x 104 (16HBE) in 96-well plates one day before transfection
to reach 80–90% confluence. MetLuc SNIM1 RNA or EGFP SNIM RNA were complexed with
branched PEI at an N/P ratio of 6.6 (provided by ethris GmbH, Martinsried, Germany). Both
were diluted in Ampuwa (Aqua ad iniectabilia, B. Braun Melsungen AG, Melsungen, Ger-
many). 500 ng of mRNA were added per well. Transfections were performed in medium with-
out serum and antibiotics. Linear PEI derivative (jetPEI, PolyPlus, France) complexes with
mRNA were prepared in sodium chloride and incubated with cells in OptiMem. 100 ng of
mRNA were added per well. The polyplexes were incubated with cells for 2 h.
Nebulisation experiments
Nebulisation experiments were conducted using a PARI Boy Nebulizer (PARI GmbH, Ger-
many) as described previously [4]. Before the nebulisation process, part of the mRNA com-
plexes was kept apart and further used as a non-nebulised control. The nebuliser was filled
with 2 ml of the complex preparations. The nebulisation was performed for 5 min.
Luciferase activity measurements
Cell supernatants were collected at different time points following transfection. Fresh media
was added to the cells after collecting the samples. 50 μl of the supernatants were mixed with
50 μl of the Metridia luciferase substrate (coelenterazine, Invivogen, France). The luciferase
activity was determined by measuring emitted light with a luminometer (FLUOstar OPTIMA,
BMG LABTECH, Germany). Luciferase activity is expressed in relative light units (RLU).
To determine the number of transfected cells EGFP expression was evaluated by means of
fluorescence microscopy (Zeiss Axiovert 200 M, Carl Zeiss Microscopy GmbH, Germany) as
well as by flow cytometry (FACSCanto, BD Bioscience, Germany) 24 h post transfection. For
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flow cytometry analysis, the cells were washed with PBS, detached by exposure to trypsin and
suspended in a flow buffer (PBS with 2% FCS, 2mM EDTA, 0,005% NaN3; Sigma Aldrich,
Munich, Germany). Dead cells were excluded based on 7-AAD staining (eBioscience, Ger-
many). 10 000 live cells per sample were analysed. Data were analysed with FCS Express 4 Flow
Cytometry software (De Novo Software, USA).
Cytotoxicity assay
Cytotoxicity of mRNA complexes was evaluated using a MTT assay according to the manufac-
turer’s instructions (Roche Diagnostics, Germany).
Statistical analysis
All results are presented as means ± standard error of the mean (SEM). For comparisons
between different groups, an ANOVA followed by Bonferroni test was executed. For compari-
sons of differences between two groups, a t- test has been performed. p< 0.05 was considered
to be significant. Statistical analyses were performed with GraphPad Prism 6 (GraphPad Soft-
ware Inc., La Jolla, USA).
Results and Discussion
Functionality of IVT mRNA after nebulisation
One of the huge challenges in delivery of nucleic acids is the route of administration. The lung
with its large surface area seems to be an attractive target site for the delivery of nucleic acids,
especially for lung diseases. A simple approach to reach the lung is the aerosolisation/nebulisa-
tion which is already performed for drugs such as antibiotics [21]. Even for pDNA complexed
with lipids the aerosolisation is already used in a gene therapy trial for Cystic Fibrosis [2]. How-
ever, no studies are available if the nebulisation of mRNA is feasible, although this molecule is
of great interest regarding vaccination, substitution of mutated genes or anti-cancer therapies
[14]. Therefore, our aim was to investigate the administration of IVT mRNA into the lung for
therapeutic approaches.
To examine the functional integrity of nebulised IVT mRNA complexes, their transfection
efficiencies were evaluated in human bronchial epithelial cells (16HBE). The complexes were
prepared by mixing IVT mRNA encoding Metridia luciferase with four cationic carriers, two
of them being cationic polymers (branched and linear polyethylenimine) and two cationic lip-
ids (Lipofectamine 2000 and DMRIE-C). The nucleic acid and cationic carriers were mixed at
optimised ratios ensuring maximal transfection efficiencies. Cationic lipids transfect 16HBE
cells much more efficiently than polyethylenimines (Fig 1). It should be noted, however, that
nebulised cationic lipid complexes were less efficient in transfecting bronchial epithelial cells
than non-nebulised ones. By contrast, the nebulisation process did not change the transfection
potential of the aerosolised cationic polymer complexes. Non-nebulised Lipofectamine com-
plexes (mean value 2.579.864 RLU) was more than three times more efficient in transfecting
human bronchial epithelial cells than non-nebulised DMRIE (mean value 823.921 RLU). Non-
nebulised linear PEI (mean value 344.950 RLU) performed almost 10 times better than its non-
nebulised branched derivative (mean value 35.330 RLU).
In addition to evaluating total levels of protein production we also assessed numbers of
transfected cells. To that end human bronchial epithelial cells were transfected with IVT
mRNA encoding green fluorescent protein. To visualise transfected cells, fluorescent micro-
scope pictures were acquired (Fig 2A–2D). The number of GFP transfected cells was calculated
by flow cytometry. 50.5% ± 3% of 16HBE cells were transfected in the non-nebulised group,
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38% ± 4% in the nebulised (Lipofectamine), p< 0.001. For branched PEI, only 2.8% ± 1% cells
were transfected in the non-nebulised as well as in the nebulised group (Fig 2E). There is a
reduction of luciferase activity (Fig 1) and GFP expression (Fig 2E) in the nebulised versus the
non-nebulised fraction of IVT mRNA lipoplexes. Still the lipoplexes resulted in better transfec-
tion rates in the 16 HBE cells than the polyplexes. In addition to evaluating total levels of pro-
tein production we also assessed numbers of transfected cells. To that end human bronchial
epithelial cells were transfected with IVT mRNA encoding green fluorescent protein. Transfec-
tion efficiency was evaluated by flow cytometry (Fig 2E). To visualise transfected cells, fluores-
cent microscope pictures were acquired. Our results demonstrate that the number of GFP
positive cells was reduced following nebulisation of Lipofectamine-mGFP complexes(Fig 2).
Transfection with the polyplexes resulted in less than 5% of positive cells.
It has been shown earlier that polyamines have stronger affinity to mRNA rather than
pDNA which impedes the release of mRNA from the complexes, which is essential for mRNA
translation [22]. This might explain the weaker transfection results of the polyplexes compared
to the lipoplexes when using IVT mRNA.
The results presented in Fig 1 demonstrate that the nebulised complexes prepared by mixing
cationic lipids with IVT mRNA are not as efficient at transfecting cells as those which are not
aerosolised. In an attempt to avoid this drop in activity we increased the amount of cationic lip-
ids employed for lipoplex preparation. The results of this experiment are presented in Fig 3A.
It reveals that a slight increase in the amount of Lipofectamine used to prepared lipoplexes
resulted in a better protection of IVT mRNA against sheer forces accompanying the nebulisa-
tion process (even if these lipoplexes are slightly less efficient in transfecting cells). This effect
was not observed for complexes prepared by mixing IVT mRNA with DMRIE.
Duration of protein expression after nebulisation
In view of the relatively short duration of IVT mRNA-induced protein production we were
concerned that the nebulisation process might negatively affect this parameter. Therefore, we
transfected 16HBE cells with Lipofectamine or DMRIE lipoplexes complexed with mRNA
encoding Metridia luciferase. Two different N/P ratios were tested for each carrier. The enzyme
Fig 1. Transfection efficiency in human bronchial epithelia cells (16HBE)–luciferase activity. Lipo- and
polyplexes were prepared as described in the material and methods section. A fraction of the complexes was
kept apart and used as a non-nebulised control (white bars). The rest of the solution was aerosolized for 5
minutes by employing a PARI Boy1 Nebulizer (black bars) and collected. Nebulised and non-nebulised
complexes were incubated with 16HBE cells for 2 h. Luciferase activity in 50 μl of supernatants was assayed
after 24 h and its activity is expressed in relative light units, n 6. The average relative light units have been
employed to evaluate differences between samples. 100 ng of mRNA complexed with 1.2 μl of Lipofectamine
or 1.5 μl DMRIE or 0.8 μl linPEI or 0.9 μl brPEI (500 ng) were added per well; **p < 0.001.
doi:10.1371/journal.pone.0137504.g001
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activity in cell supernatants was monitored over time. As demonstrated in Fig 4A, luciferase
activity was detected for 4 days in cells transfected with nebulised and non-nebulised Lipofecta-
mine complexes alike. Maximal levels of enzyme activity were determined 24 h post transfec-
tion followed by a gradual decrease. The same trend was observed for the cells transfected with
DMRIE complexes. It is worth mentioning that even though the initial levels of luciferase activ-
ity determined for cells transfected with DMRIE were lower than those achieved by Lipofecta-
mine, this cationic lipid ensured production of luciferase for a longer period.
Fig 2. Transfection efficiency in human bronchial epithelia cells—numbers of GFP positive cells.
Lipoplexes were prepared in OptiMem. A fraction of the complexes was kept apart and used as a non-
nebulised control. The rest of the solution was aerosolized for 5 minutes by employing a PARI Boy1
Nebulizer and collected. Nebulised and non-nebulised complexes were incubated with 16HBE cells for 2 h.
100 ng of IVT mRNA complexed with 1.2 μl of Lipofectamine or 1.5 μl of DMRIE were added per well. For
brPEI 500 ng IVT mRNA complexed with 0.9 μl brPEI were used. The numbers of GFP positive cells were
determined by flow cytometric analysis and by acquiring pictures at a fluorescent microscope. A-B non-
nebulised Lipofectamine-mGFP complexes; C-D nebulised Lipofectamine-mGFP complexes; E—numbers of
GFP-positive cells achieved by nebulised and non-nebulised Lipofectamine-GFP complexes evaluated by
flow cytometry (n = 9); F-G not nebulised DMRIE-mGFP complexes; H-I nebulised DMRIE-mGFP
complexes.
doi:10.1371/journal.pone.0137504.g002
Nebulisation of IVT mRNA Complexes for Pulmonary Administration
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Does the nebulisation process affect the toxicity induced by cationic
carrier complexes?
The potential of the nebulised complexes for therapeutic purposes can be properly interpreted
only if impending toxic effects are taken into account. Therefore the toxicity of aerosolised par-
ticles was evaluated 24 h after transfection, which is the time the cells require to produce maxi-
mal levels of the marker protein and had to deal with possible degradation products. These
results were compared with toxicities induced by non-nebulised lipoplexes. As demonstrated
in Fig 5, Lipofectamine and DMRIE lipoplexes displayed only very mild toxicities irrespective
of nebulisation.
Fig 3. Transfection efficiency in human bronchial epithelia cells—the effect of the charge ratio at
whichmRNA and cationic lipids are mixed. Lipoplexes were prepared in OptiMem. A fraction of the
complexes was kept apart and used as a non-nebulised control. The rest of the solution was aerosolized for 5
minutes by employing a PARI Boy1 Nebulizer and collected. 100 ng of mRNA encoding Metridia luciferase
were complexed with Lipofectamine (condition 1–1.2 μl; condition 2–1.8 μl) (A) or DMRIE (condition 1–1.2 μl;
condition 2–1.5 μl; condition 3–1.8 μl) (B) were added per well. Nebulised and non-nebulized complexes
were incubated with 16HBE cells for 2 h. Luciferase activity in 50 μl of supernatants was assayed with a
luminometer. The enzyme activity is expressed in relative light units, n = 5. *p < 0.01; **p < 0.001.
doi:10.1371/journal.pone.0137504.g003
Nebulisation of IVT mRNA Complexes for Pulmonary Administration
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Influence of the carrier solution for IVT mRNA for transfection efficiency
Since future applications in patients will require administration of IVT mRNA complexes in
solutions other than cell culture media, we also evaluated transfection efficiency of IVT mRNA
Fig 4. Transfection efficiency in human bronchial epithelia cells—duration of protein production.
Lipoplexes were prepared in OptiMem. A fraction of the complexes was kept apart and used as a non-
nebulised control. The rest of the solution was aerosolized for 5 minutes by employing a PARI Boy1
Nebulizer and collected. 100 ng of IVT mRNA encoding Metridia luciferase were complexed with
Lipofectamine (condition 1–1.2 μl; condition 2–1.8 μl) or DMRIE (condition 1–1.2 μl; condition 2–1.5 μl) and
added per well. Nebulised and non-nebulised complexes were incubated with 16HBE cells for 2 h. Luciferase
activity in 50 μl of supernatants was assayed every 24 h till the relative light units measured with a
luminometer dropped below 100. The media were replaced daily after collecting samples for analysis.
Enzyme activity is expressed in relative light units, n = 6.
doi:10.1371/journal.pone.0137504.g004
Fig 5. Cell toxicities of mRNA lipoplexes. Lipoplexes were prepared in OptiMem. A fraction of the
complexes was kept apart and used as a non-nebulised control. The rest of the solution was aerosolized for 5
minutes by employing a PARI Boy1 Nebulizer and collected. 100 ng of IVT mRNA encoding Metridia
luciferase were complexed with Lipofectamine (condition 1–1.2 μl; condition 2–1.8 μl) or DMRIE (condition
1–1.2 μl; condition 2–1.5 μl) and added per well). Nebulised and non-nebulised complexes were incubated
with 16HBE cells for 2 h. An MTT assay was performed 24 h post transfection. n = 6.
doi:10.1371/journal.pone.0137504.g005
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complexes diluted in 0.9% sodium chloride, which is a typical solution for drug delivery via
nebulisation. To that end human bronchial epithelial cells were transfected with Lipofecta-
mine-lipoplexes dispersed in sodium chloride. Not unexpectedly transfection efficiencies
achieved by complexes diluted in sodium chloride were lower than those obtained by IVT
mRNA complexes dispersed in OptiMem (Fig 6). In addition, luciferase activity could be also
detected for a slightly shorter period of time. However, the nebulised Lipofectamine complexes
prepared in sodium chloride were more or at least equally efficient at transfecting human bron-
chial epithelial cells than non-nebulised ones.
Messenger RNA is generally considered a very unstable molecule. This assumption limited
its employment as a tool to transfect cells for a long time. Nonetheless, it has been demon-
strated by several groups that complexes made of IVT mRNA and cationic carriers can trans-
fect different cell types very efficiently [9, 23]. However, its efficient and safe in vivo delivery
remains to be unequivocally established. Therefore, we set out to define optimal conditions for
the preparation of IVT mRNA complexes with cationic carriers that are maximally stable dur-
ing the nebulisation process. Here, we could demonstrate that IVT mRNA complexed with cat-
ionic lipids or cationic polymers can resist shear forces during nebulisation. Lipid-IVT mRNA
complexes resulted in a slightly lower transfection rate than polymer-IVT mRNA complexes.
In general the rate of achieved transfection was higher when employing cationic lipids com-
pared with cationic polymers. Also the duration of protein expression was independent of the
nebulisation process. First of all, we compared lipids and polymers regarding their ability of
protecting mRNA during the nebulisation process. No significant decrease in transfection effi-
ciency was observed by using polyplexes such as linear and branched PEI, whereas a significant
reduction was measured for lipoplexes (Lipofectamine 2000 as well as DIMRIE). However, lip-
ids showed a much higher transfection rate in general. This was confirmed by determining the
number of transfected cells. To overcome the drop in transfection efficiency during nebulisa-
tion, it is possible to slightly increase the amount of cationic lipids complexed with mRNA.
However, we could only demonstrate this effect with Lipofectamine 2000 and not by increasing
the amount of DMRIE. Furthermore, the nebulisation process did not indicate cytotoxic effects
Fig 6. Effect of different solutions on the transfection efficiency of lipoplexes. Lipoplexes were
prepared in OpiMem but diluted in sodium chloride solution (0.9%). A fraction of the complexes was kept
apart and used as a non-nebulised control. The rest of the solution was aerosolized for 5 minutes by
employing a PARI Boy1 Nebulizer and collected. 100 ng of IVT mRNA encoding Metridia luciferase were
complexed with 1.2 μl of Lipofectamine and subsequently added per well. Nebulised and non-nebulised
complexes were incubated with 16HBE cells for 2 h. Luciferase activity in 50 μl of supernatants was assayed
every 24 h till the relative light units measured with a luminometer dropped below 100. The media on the cells
were replaced daily after collecting samples for analysis. Enzyme activity is expressed in relative light units.
n = 5; *p < 0.01.
doi:10.1371/journal.pone.0137504.g006
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and showed the same duration time of protein production (four days for Lipofectamine 2000
and five days for DIMRIE). Although the preparation of lipoplexes in 0.9% sodium chloride
was not as efficient as in OptiMem, no reduction in transfection efficiency was observed
between the nebulised and non-nebulised samples.
Conclusions
In conclusion, our results show that nebulisation of cationic IVT mRNA complexes does not
lead to significant detrimental effects on the transfection potency of the IVT mRNA nor does it
cause toxic effects on the transfected cells. Thus, it can be concluded that aerosol preparations
of cationic IVT mRNA complexes constitute a potential powerful means to transfect cells in
the respiratory tract, including the lung, with the purpose to beneficially modulate the function
of such cells in case of diseases such as cystic fibrosis or alpha-1-antitrypsin deficiency, while
bringing along the advantages of IVT mRNA as compared to pDNA as transfection agent.
Together these findings indicate that IVT mRNA complexes can be nebulized and identify this
mode of administration as an attractive innovative route of administration for clinical use
within the field of protein substitution and vaccination approaches.
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